{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fpce.simplecast.com%2Fepisodes%2Fasco-2022-mcl-7N89L5OU","width":444,"version":"1.0","type":"rich","title":"ASCO 2022: What’s New in Mantle Cell Lymphoma\t","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/4c659596-dddf-4d83-8715-1e0d96d10695/mcl-asco-cc-podcasticon.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/3efcc000-f0b2-428b-aef9-b799ff389c91\" height=\"200\" width=\"100%\" title=\"ASCO 2022: What’s New in Mantle Cell Lymphoma \" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast episode, listen to Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, discuss key data for mantle cell lymphoma presented at the 2022 ASCO annual meeting, including data on BTK inhibitors, CAR T-cell therapy, and other novel agents targeting ROR1."}